Plerixafor

Generic Name
Plerixafor
Brand Names
Mozobil, Plerixafor Accord
Drug Type
Small Molecule
Chemical Formula
C28H54N8
CAS Number
110078-46-1
Unique Ingredient Identifier
S915P5499N
Background

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...

Indication

Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.

Associated Conditions
-
Associated Therapies
Mobilization of hematopoietic stem cells
Clinical Trials
Related News

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

First Posted Date
2021-10-21
Last Posted Date
2024-02-20
Lead Sponsor
Stanford University
Target Recruit Count
40
Registration Number
NCT05088356
Locations
🇺🇸

Stanford University, Stanford, California, United States

Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Phase 2
Withdrawn
Conditions
Sickle Cell Disease
Interventions
Drug: Plerixafor
First Posted Date
2021-03-26
Last Posted Date
2023-04-07
Lead Sponsor
St. Jude Children's Research Hospital
Registration Number
NCT04817345

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

First Posted Date
2021-02-21
Last Posted Date
2024-11-06
Lead Sponsor
Ensoma
Target Recruit Count
7
Registration Number
NCT04762875
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Stanford Health Care, Stanford, California, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 5 locations

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: MGTA-145
Drug: Plerixafor
First Posted Date
2020-09-17
Last Posted Date
2022-09-10
Lead Sponsor
Surbhi Sidana, MD
Target Recruit Count
25
Registration Number
NCT04552743
Locations
🇺🇸

Stanford University, Stanford, California, United States

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

First Posted Date
2019-11-26
Last Posted Date
2024-02-23
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
25
Registration Number
NCT04177810
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

First Posted Date
2018-11-19
Last Posted Date
2024-06-26
Lead Sponsor
Lawrence D Recht
Target Recruit Count
21
Registration Number
NCT03746080
Locations
🇺🇸

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

Phase 1
Active, not recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: Plerixafor
First Posted Date
2018-09-11
Last Posted Date
2024-10-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
5
Registration Number
NCT03664830
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

First Posted Date
2018-06-06
Last Posted Date
2019-09-17
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
17
Registration Number
NCT03547830
Locations
🇷🇺

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

First Posted Date
2018-04-24
Last Posted Date
2020-07-24
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT03506802
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Completed
Conditions
Multiple Myeloma
Interventions
Drug: Plerixafor
First Posted Date
2018-01-23
Last Posted Date
2024-02-20
Lead Sponsor
Fondazione EMN Italy Onlus
Target Recruit Count
300
Registration Number
NCT03406091
Locations
🇮🇹

A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy